Evidence map›Paper›PMID 37957370›Full record

ArticleAnnals of hematology2024

Zanubrutinib-lenalidomide-rituximab (ZR

Yawen Wang, Jiadai Xu, Panpan Li, Yanyan Xu, Hongwei Xue, Peng Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yawen Wang *Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiadai Xu *Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Panpan Li *Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yanyan XuDepartment of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hongwei XueDepartment of Hematology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. hwx326@sina.com.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China. liu.peng@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-9639-6606
Qingdao University · CNSun Yat-sen University · CNFudan University · CNShanghai Jiao Tong University · CN

Funding

Cancer Research Foundation of Huiyu Pharmaceutical GH000027National Natural Science Foundation of China 82100215Natural Science Foundation of Shanghai 22ZR1411400Youth Foundation of the Affiliated Hospital of Qingdao University QDFYQN 202101009
6 · The paper itself

Abstract

The objective of this study is to examine the effectiveness and safety of zanubrutinib, rituximab, and lenalidomide (ZR

Indexed as

Lymphoma, Large B-Cell, DiffusePiperidinesPyrazolesPyrimidinesThrombosisAgedAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomidePlatelet Aggregation InhibitorsRetrospective StudiesRituximabThalidomideLenalidomidePiperidinesPlatelet Aggregation InhibitorsPyrazolesPyrimidinesRituximabThalidomidezanubrutinibBleeding eventsDLBCLLenalidomidePlatelet functionsUnfitZanubrutinib

Identifiers

PMID37957370
OpenAlexW4388647710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.